Ignite Creation Date:
2025-12-24 @ 5:00 PM
Ignite Modification Date:
2026-01-04 @ 4:56 PM
Study NCT ID:
NCT03558750
Status:
TERMINATED
Last Update Posted:
2019-04-25
First Post:
2018-06-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-06-14
Start Date Type:
ACTUAL
Primary Completion Date:
2019-04-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-04-16
Completion Date Type:
ACTUAL
First Submit Date:
2018-06-04
First Submit QC Date:
None
Study First Post Date:
2018-06-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-23
Last Update Post Date:
2019-04-25
Last Update Post Date Type:
ACTUAL